🇺🇸 FDA
Pipeline program

ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red

CBYL719C2303

Phase 3 small_molecule active

Quick answer

ALPELISIB, FULVESTRANT, ALPELISIB, Placebo to BYL719 50 mg film-coated tablet Light pink Placebo to BYL719 200 mg film-coated tablet Light red for Hormone receptor positive, HER2-negative advanced breast cancer is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).

Program details

Company
Novartis Ophthalmics Europe
Indication
Hormone receptor positive, HER2-negative advanced breast cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials